No Data
Sector Update: Health Care Stocks Mixed Premarket Monday
Sector Update: Health Care
Express News | SpringWorks Therapeutics Inc - in H2 2024, Plans to File Marketing Authorization Application With EMA for Mirdametinib
Express News | SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults With Nf1-Pn
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
TD Cowen analyst Yaron Werber maintains $SpringWorks Therapeutics(SWTX.US)$ with a buy rating, and maintains the target price at $63.According to TipRanks data, the analyst has a success rate of 57.8%
Express News | SpringWorks Therapeutics Inc : JP Morgan Cuts Target Price to $64 From $77